
- Telehealth Visits
- Insurance plan information

Rahul Aggarwal, MD
Genitourinary Medical Oncology- Telehealth Visits
- Insurance plan information



Rahul Aggarwal, MD
Genitourinary Medical Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.
As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.
Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.
Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Fellowship
- Hematology - Oncology, UCSF Medical Center - OMAG
Internship
- Internal Medicine, UCSF Medical Center - OMAG
Degree
- MD, Northwestern University Feinberg School of Medicine
My expertise
Locations
My research
Clinical trials
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsOpens in a new window
Recruiting
• TEAEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.5.0.177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate CancerOpens in a new window
Recruiting
Treatment emergent adverse events will be classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events and clini...Imaging of Solid Tumors Using 18F-TRXOpens in a new window
Recruiting
The proportion of participants with any treatment-emergent adverse events will be reported by grade and frequency per the NCI Common Terminology Criteria for A...A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Opens in a new window
Recruiting
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progressi...
Publications
Showing 1-6 of 57 reviews
- March 27, 20264.9 out of 5 Stars
My experience over the four years has been very good
- March 11, 20265 out of 5 Stars
This cancer team that has my case is the most responsive and caring team a trial patient could have. I feel safe!
- February 28, 20265 out of 5 Stars
I have had excellent support throughout my Cancer treatment for the last 10 years. Dr. Aggarwal is Terrific!!!!
- February 16, 20265 out of 5 Stars
I am extremely grateful to have Dr. Aggarwal as a primary consultant for my medical care!
- February 4, 20265 out of 5 Stars
In my estimation I am receiving World Class Care!
- January 16, 20265 out of 5 Stars
Dr. Aggarwal was exceptionally personal, professional, knowledgeable, and helpful
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.